A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Erlotinib (Primary) ; Pictrelisib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 15 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Dec 2013 Planned end date changed from 1 Oct 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 09 Sep 2013 Planned end date changed from 1 Apr 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.